熱門資訊> 正文
ViiV报告了艾滋病毒预防药物的积极现实数据
2024-10-17 00:26
- ViiV Healthcare, which is co-owned by GSK (NYSE:GSK), Pfizer (NYSE:PFE) and Shionogi, said real-world studies showed its drug Apretude was more than 99% effective as a pre-exposure prophylaxis, or PrEP, treatment for the prevention of HIV infection.
- The company said the data underscored the high adherence rate and effectiveness of Apretude, a long-acting formulation of cabotegravir. The data will be presented at the IDWeek 2024 conference, which is being held Oct. 16-19 in Los Angeles, according to a statement.
- ViiV is majority owned by GSK (GSK). Pfizer (PFE) and Shionogi are also shareholders.
More on GSK, Pfizer, etc.
- GSK: The Worst Is Finally Over (Rating Upgrade)
- Pfizer: Investor Activism Is Not The Solution
- Pfizer: A 6% Yielding Ultra SWAN Bargain With Upside Potential
- Wave stock soars 66% on positive data for RNA editing treatment (update)
- GSK antibiotic for UTI accepted for FDA priority review
推薦文章
華盛早報丨重大突破！三大加密貨幣法案眾議院闖關成功；美聯儲，降息大消息
黃仁勛年內三度訪華！H20重返中國市場，釋放了什麼信號？
美股機會日報 | 6月零售數據高於市場預期；臺積電績后漲超3%
美股「七巨頭」迎特朗普關稅后首次大考！Q2能否交出亮眼成績單，繼續引領美股上漲？
華盛早報丨TACO交易再現！特朗普閃電改口「解僱鮑威爾」；美國眾議院加密貨幣立法進程受阻
財報前瞻 | 特斯拉Q2營收料下滑10%！股價銷量雙殺下，馬斯克能否逆轉局勢？
美股機會日報 | 低於市場預期！美國6月PPI同比增長2.3%；特斯拉官宣Model Y L
華盛早報丨事關中美關税！美財長最新放風；「加密周」突發！多項加密貨幣法案遭眾議院否決
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
